The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved October 1997

Specific Treatments:

benign prostatic hypertrophy (BPH)

General Information

FLOMAX has been approved for the treatment of benign prostatic hypertrophy (BPH). Boehringer Ingelheim, which licensed the product from originator Yamanouchi, will market the product in the U.S.


[ Home | Discussions | Article Archives | Help | Submit your Site]

Copyright 1996 - 2014 by Gelber Associates All Rights Reserved.